NCT06332170 - ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

610

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

HS-20093

administered as an IV infusion

DRUG

Adebrelimab

administered as an IV infusion

DRUG

Cisplatin/ Carboplatin

administered as an IV infusion

DRUG

Cetuximab

administered as an IV infusion

DRUG

Enzalutamide

160mg once daily (QD) orally

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY